Search PubMed⌕ Search

Biomedical subjects

A Scommegna

Publications and source records attributed to A Scommegna.

100 records · Page 6Linked to original sources
PubMed1967

Urinary pregnanediol and creatinine excretion in the female of menstrual age.

The urinary pregnanediol and creatinine excretions in females of menstrual age were correlated. The high degree of correlation found allows the use of the pregnanediol/creatinine ratio of the first-morning voided urinary specimen in calculating, with a fair degree of precision, the 24-hr. pregnanediol excretion.

Adolescent↗
PubMedDate not supplied

Altered newborn gender distribution in patients with low mid-trimester maternal serum human chorionic gonadotropin (MShCG).

OBJECTIVE: to determine if the sex ratio (male/female) is altered in infants born to patients with low mid-trimester maternal serum human chorionic gonadotropin (MShCG). STUDY DESIGN: Between 2/1/90 and 1/3/91, 3,116 patients underwent prenatal screening using second-trimester maternal serum alpha-fetoprotein (MSAFP), MShCG, and maternal serum unconjugated estriol (MSuE3). Among these, there were 132 patients with low second-trimester MShCG (< 0.4 MoM), normal MSAFP and MSuE3. The gender distribution of these term, normal newborns was compared to that of 237 controls, matched for race, maternal age, and referral source and delivered at term to mothers with normal mid-trimester MSAFP, MSuE3, and MShCG. The gender distribution of these two groups of newborns was also compared to that of 78 term newborns from the same obstetrical population delivered to mothers with second-trimester MShCG > 2.5 MoM and normal MSAFP and MSuE3. All patients had a complete obstetrical history. RESULTS: Forty-nine percent of the controls were male vs. 62% of the group with slow second-trimester MShCG (P < .01). Within the group with low MShCG, 59% of infants were male when the MShCG was between 0.19 and 0.4 MoM (A) and 80% when the MShCG was < 0.2 MoM (B) (control vs. A vs. B P < .005). The sex ratio in the high-MShCG group was similar to control. CONCLUSION: The data suggest that gender distribution is different from normal in patients with low mid-trimester MShCG.

Chorionic Gonadotropin↗
PubMedDate not supplied

Effect of oral estriol on abnormal plasma FSH and LH concentrations in women with unexplained infertility; conception in a patient with elevated FSH and LH.

Estriol tablets in the daily dose of 0.25, 0.5 or 1.0 mg were administered for ten days prior to the expected ovulation in six women with unexplained, long-standing infertility, regular, apparently ovulatory cycles, and normal cyclic changes in estradiol and progesterone. Five of six had abnormal FSH and LH patterns contrasting with normal estradiol and progesterone secretion during the control cycle. There was an increase in the midcycle LH surge at two lower doses of estriol and at the highest dose there was a 7-9 day delay observed in the estradiol peak, LH surge and menstrual period in the patient with the normal control cycle. This contradicts previously published data that estriol does not suppress or delay ovulation at the dose as high as 6 mg/day. In four patients with persistently elevated LH and low FSH concentrations, there was little change in the pattern of FSH, LH, estradiol or progesterone secretion during treatment. In the last patient, who had during the control cycle plasma FSH and LH concentrations fluctuating between high normal and menopausal range, indicating "premature ovarian failure" and absence of ovarian follicles, essentially normal cyclic pattern of both gonadotropins with exception of few individual values appeared during treatment. The patient conceived during the last cycle of treatment (estriol 1.0 mg/day). Our study demonstrates that high concentrations of FSH and LH may not necessarily indicate the absence of oocytes and documents previously reported, but never documented occurrence of a conception during estrogen therapy in such a case.

Dose-Response Relationship, Drug↗